Alicia Zhou, Ph.D., the incoming CEO at the Cancer Research Institute, talks about her plans and approach to moving a 70-year ...

In three years, Carisma Therapeutics has gone public, entered a broad collaboration with Moderna, and ceased development of ...

Melissa Leichter, a Novo Nordisk executive, describes the distinct skills and mindset needed to succeed in bringing rare disease treatments to market.

Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...

Single-use (SU) systems show significant promise for antibody-drug conjugate (ADC) manufacturing. However, the use of organic solvents in the ADC process raises concerns about potential leachables ...

Effective provider segmentation can make or break a new drug launch, and can also improve the lifecycle of existing portfolio ...

We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...

The rapid adoption of AI in the pharmaceutical market has led to a revolution in the research process and pharmaceutical development techniques. The AI revolution is not free of risks, however. This ...